Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Celldex Therapeutics

Key Facts as at 30.09.2025

Company locationUSA
Size in % of securities3.30%
Size of stake in company5.40%
Market capitalizationUSD 1.7 bn

Sector

Inflammation

Main candidate

Barzolvolimab

Main indications

Urticaria and other mast cell driven diseases 

About the company

Celldex Therapeutics is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. The pipeline includes antibody-based therapeutics that have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. The company's lead product candidate Barzolvolimab is a first in class Fc silenced human IgG1 monoclonal antibody (mAb) against wildtype c-KIT receptor leading to depletion and/or inhibition of mast cell activation. The company is on track to start Phase III barzolvolimab clinical development in Chronic spontaneous Urticaria during 2024 and to report Phase II clinical data in Chronic Inducible Urticaria as well as Eosinophilic Esophagitis.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.